N/A
N=132
Genotypic and Phenotypic Correlates of Resistance to Aspirin
Platelet Dysfunction Due to Aspirin
Bottom Line
View on ClinicalTrials.gov: NCT01361620 ↗Enrolled (actual)
132
Serious AEs
0.0%
Results posted
Dec 2013
Primary outcome: Primary: Whole Blood Coagulation — 453.8 Aspirin response units (ARU)
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- aspirin (Drug)
- Age
- Adult, Older Adult · 40+ yrs
- Sex
- All
- Sponsor
- George Washington University
- Primary completion
- Apr 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Whole Blood Coagulation |
453.8 | — |
Summary
The study seeks to identify genomic markers associated with aspirin resistance.
Eligibility Criteria
Inclusion Criteria
- Volunteers 40 to 80 years old willing to sign consent and take 81 mg of aspirin for 7 - 10 days and return for laboratory testing.
Exclusion Criteria
- Patient requiring more than 81 mg aspirin daily
- Known GI bleeding attributed to ASA
- Active peptic ulcer disease or history within the last year
- Known aspirin allergy
- Current use of:
- warfarin,
- heparin,
- NSAIDs (except aspirin),
- clopidogrel,
- dipyridamole,
- fish-oil/omega 3 supplements,
- Women of childbearing potential who are pregnant, planning to become pregnant or nursing.
Data sourced from ClinicalTrials.gov (NCT01361620). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.